Every pharma marketing team builds MLR time into their campaign plans. It's standard practice — you add four to eight weeks for review, maybe more for complex materials, and you design your launch timeline around it. The assumption embedded in this planning habit is that MLR review takes as long as it takes, and the job of project management is to accommodate that reality.
This assumption is wrong — or rather, it's only partly right. Some MLR time is unavoidable. Medical, Legal, and Regulatory review is rigorous because it needs to be — FDA's Office of Prescription Drug Promotion exists specifically to ensure prescription drug promotional materials are truthful, balanced, and accurately communicated, and every submission is reviewed against that standard. But a significant portion of what gets absorbed into "MLR time" isn't review time. It's version confusion time. And that part is avoidable.
Version-related delays in MLR review compound in ways that are hard to track because they don't appear as a discrete line item in a project plan. A reviewer sends comments on a document that was superseded the previous day. The marketing team reconciles those comments with the current version, produces a new file, and resubmits. The reviewer, now unclear on exactly what changed, requests another full review. The cycle repeats.
Industry analysis consistently identifies this pattern as a primary driver of MLR cycle length. Review cycles that run to multiple months are widely documented in pharmaceutical marketing operations — and the portion driven by version misalignment, rather than substantive review time, is where the most meaningful compression is available.
When a campaign misses its launch window because of MLR revision cycles, that cost isn't usually calculated. It gets absorbed into the annual plan as "how things work." The media booking that wasn't used. The HCP communications that went out after the peak prescribing period. The congress materials that arrived after the event.
These are real commercial consequences of a process inefficiency that the industry has normalized to the point of invisibility. The version alignment time — not the review time itself — is where the most recoverable delay sits. Process redesign that addresses version control rather than reviewer throughput is where meaningful cycle-time reduction comes from.
The change isn't adding more reviewers or running faster review cycles. It's ensuring that every document entering the MLR workflow is the same, controlled, verified version — and that any subsequent change triggers a documented comparison before the revised material is resubmitted. When Medical, Legal, and Regulatory each receive the same version, and when revisions are tracked rather than informally distributed, review cycles compress naturally.
↗ InformaIT's Content Compare eliminates the version alignment problem in MLR workflows. Request a demo to see the difference.